0000000000930207

AUTHOR

Urs Fischer

showing 6 related works from this author

Availability of secondary prevention services after stroke in Europe: An ESO/SAFE survey of national scientific societies and stroke experts

2018

Background Recurrent stroke is associated with increased disability and cognitive impairment, but the availability of secondary prevention measures after transient ischaemic attack (TIA) or stroke in Europe is uncertain. This limits prioritisation of investment and development of national stroke strategies. Methods National stroke representatives throughout Europe were surveyed. Consensus panels reported national data if available, or else expert opinion, estimating the availability of each intervention by quintiles of patients, dichotomised for analysis at 60%. Countries were classified into tertiles of gross domestic product per capita. Results Of 50 countries, 46 responded; 14/45 (31%) h…

Secondary preventionmedicine.medical_specialtybusiness.industry610 Medicine & healthmedicine.diseasestroke3. Good healthEurope03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationOriginal Research Articlesmedicine030212 general & internal medicineNeurology (clinical)SurveyCardiology and Cardiovascular MedicineCognitive impairmentbusinessStrokesecondary prevention030217 neurology & neurosurgery
researchProduct

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients

2020

Background and Purpose— We aimed to determine the safety and mortality after mechanical thrombectomy in patients taking vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs). Methods— In a multicenter observational cohort study, we used multiple logistic regression analysis to evaluate associations of symptomatic intracranial hemorrhage (sICH) with VKA or DOAC prescription before thrombectomy as compared with no anticoagulation. The primary outcomes were the rate of sICH and all-cause mortality at 90 days, incorporating sensitivity analysis regarding confirmed therapeutic anticoagulation. Additionally, we performed a systematic review and meta-analysis of literature on this to…

MaleMESH: RegistriesAdministration Oral030204 cardiovascular system & hematology0302 clinical medicineInterquartile rangeMESH: ThrombectomyRegistriesStrokeThrombectomyMESH: AgedMESH: Middle AgedMESH: Follow-Up StudiesMiddle Aged3. Good healthddc:StrokeMESH: Administration OralFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Cardiology and Cardiovascular MedicineMESH: Intracranial HemorrhagesCohort studymedicine.medical_specialty610 Medicine & healthMESH: AnticoagulantsLower riskMESH: Stroke03 medical and health sciencesMeta-Analysis as TopicInternal medicinemedicineHumansMESH: Meta-Analysis as TopicMedical prescriptionAgedAdvanced and Specialized NursingMESH: Humansbusiness.industryAnticoagulantsOdds ratiomedicine.diseaseFactor Xa inhibitorsMESH: MaleStroke treatmentIntracranial hemorrhagesObservational studyNeurology (clinical)MESH: Systematic Reviews as TopicbusinessMESH: Female030217 neurology & neurosurgeryFollow-Up StudiesSystematic Reviews as Topic
researchProduct

Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.

2022

Background:No study has so far compared Amulet with the new Watchman FLX in terms of residual left atrial appendage (LAA) patency or clinical outcomes in patients undergoing percutaneous LAA closure.Methods:In the investigator-initiated SWISS APERO trial (Comparison of Amulet Versus Watchman/FLX Device in Patients Undergoing Left Atrial Appendage Closure), patients undergoing LAA closure were randomly assigned (1:1) open label to receive Amulet or Watchman 2.5 or FLX (Watchman) across 8 European centers. The primary end point was the composite of justified crossover to a nonrandomized device during LAA closure procedure or residual LAA patency detected by cardiac computed tomography angiogr…

medicine.medical_specialtyCardiac CatheterizationPercutaneouslaw.inventionRandomized controlled triallawLeft atrialPhysiology (medical)Atrial FibrillationmedicineClinical endpointHumansIn patientAtrial AppendageThrombusCardiac Surgical Procedures610 Medicine & healthbusiness.industrymedicine.diseaseSurgeryClinical trialTreatment OutcomeRelative riskCardiology and Cardiovascular MedicinebusinessEchocardiography Transesophageal
researchProduct

Artery occlusion independently predicts unfavorable outcome in cervical artery dissection

2020

ObjectiveTo assess the impact of dissected artery occlusion (DAO) on functional outcome and complications in patients with cervical artery dissection (CeAD).MethodsWe analyzed combined individual patient data from 3 multicenter cohorts of consecutive patients with CeAD (the Cervical Artery Dissection and Ischemic Stroke Patients [CADISP]–Plus consortium dataset). Patients with data on DAO and functional outcome were included. We compared patients with DAO to those without DAO. Primary outcome was favorable functional outcome (i.e., modified Rankin Scale [mRS] score 0–1) measured 3–6 months from baseline. Secondary outcomes included delayed cerebral ischemia, major hemorrhage, recurrent CeAD…

AdultMalemedicine.medical_specialtyCervical Arterymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationArticle03 medical and health sciences0302 clinical medicineInterquartile rangeModified Rankin ScaleAneurysm DissectingInternal medicineHumansMedicineArtery occlusionStrokeAgedbusiness.industryOdds ratioRecovery of FunctionMiddle Agedmedicine.disease3. Good healthAortic DissectionCerebrovascular DisordersDissectionVINTAGECerebrovascular DisorderCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCerebral Arterial DiseasesNeurology (clinical)businessCerebral Arterial Disease030217 neurology & neurosurgeryHuman
researchProduct

The state of stroke services across the globe: Report of World Stroke Organization–World Health Organization surveys

2021

Background Improving stroke services is critical for reducing the global stroke burden. The World Stroke Organization–World Health Organization– Lancet Neurology Commission on Stroke conducted a survey of the status of stroke services in low and middle-income countries (LMICs) compared to high-income countries. Methods Using a validated World Stroke Organization comprehensive questionnaire, we collected and compared data on stroke services along four pillars of the stroke quadrangle (surveillance, prevention, acute stroke, and rehabilitation) in 84 countries across World Health Organization regions and economic strata. The World Health Organization also conducted a survey of non-communicabl…

Gerontologymedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectGlobeCommissionstroke quadrangleGlobal HealthWorld Health OrganizationWorld healthArticleStroke servicerehabilitationlow and middle-income countrie03 medical and health sciences0302 clinical medicineState (polity)preventionAcute careSurveys and QuestionnairesmedicineHumans030212 general & internal medicinehigh-income countrieStrokeDeveloping Countriesmedia_commonStroke servicesRehabilitationbusiness.industryStroke Rehabilitationmedicine.disease3. Good healthStrokemedicine.anatomical_structureNeurologylow- and middle-income countrieSettore MED/26 - Neurologiaacute carebusiness030217 neurology & neurosurgery
researchProduct

Primary stroke prevention worldwide:translating evidence into action

2021

Abstract: Stroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, includin…

Global Burden of Disease03 medical and health sciences0302 clinical medicineNursingBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Neurology.Medicine030212 general & internal medicineStrokeHealth policyCause of deathEntire populationHealth professionalsbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Neurologija.medicine.disease3. Good healthStrokeAction (philosophy)Stroke preventionOcclusive Cerebrovascular DiseaseLife course approachHuman medicinebusiness030217 neurology & neurosurgery
researchProduct